Tretinoin · Vesanoid

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (39)
Acute Myeloid Leukemia
NCT02339740 · Children's Oncology Group
2015-07-21 – 2029-06-30 · Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
What this study did
NCT05654194 · The First Affiliated Hospital of Soochow University
2022-10-31 – 2026-02-28 · Acute Myeloid Leukemia
What this study did
NCT02688140 · Technische Universität Dresden
2016-06 – 2025-01-20 · Acute Promyelocytic Leukemia
What this study did
NCT02899169 · First Affiliated Hospital Xi'an Jiaotong University
2016-09-01 – 2022-11-01 · Acute Promyelocytic Leukemia
What this study did
NCT00866918 · Children's Oncology Group
2009-03-09 – 2022-09-30 · Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
What this study did
NCT00482833 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2007-08 – 2019-10-17 · Leukemia
What this study did
NCT01226303 · Associazione Italiana Ematologia Oncologia Pediatrica
2009-01 – 2018-12 · Acute Promyelocytic Leukemia
What this study did
NCT00378365 · Assistance Publique - Hôpitaux de Paris
2006-10 – 2016-09 · Leukemia, Promyelocytic, Acute
What this study did
NCT01067274 · Acute Leukemia French Association
2010-04 – 2016-04 · Acute Myeloid Leukemia
What this study did
NCT00002658 · Medical Research Council
started 1994-01 · Leukemia, Neutropenia
What this study did
NCT00002701 · European Organisation for Research and Treatment of Cancer - EORTC
started 1995-10 · Leukemia
What this study did
NCT00151255 · University of Ulm
2004-06 – 2011-01 · Acute Myeloid Leukemia
What this study did
NCT00005823 · Leukemia Research Fund
1998-12 – 2007-12 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
What this study did
NCT00003934 · National Cancer Institute (NCI)
1999-06 – 2006-11 · Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3), Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
What this study did
NCT00005863 · Medical Research Council
1998-08 – 2004-12 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
What this study did
Other / comorbidity
NCT06706401 · Centre Leon Berard
2025-02-20 – 2029-01 · Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
What this study did
NCT07597395 · Peking University People's Hospital
2026-05-30 – 2028-12-30 · Immune Thrombocytopenia
What this study did
NCT00392327 · Children's Oncology Group
2007-05-23 – 2026-03-31 · Anaplastic Medulloblastoma, Medulloblastoma
What this study did
NCT05438875 · Peking University People's Hospital
2022-10-12 – 2024-11-30 · Purpura, Thrombocytopenic, Idiopathic
What this study did
NCT06213987 · Srinakharinwirot University
2024-02-01 – 2024-06-01 · Acanthosis Nigricans, Hyperpigmentation
What this study did
NCT00567567 · Children's Oncology Group
2007-11-05 – 2022-03-31 · Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
What this study did
NCT00499616 · Children's Oncology Group
2007-10-08 – 2021-06-30 · Neuroblastoma
What this study did
NCT01041638 · National Cancer Institute (NCI)
2009-12-21 – 2021-06-30 · High Risk Neuroblastoma
What this study did
NCT01882127 · Shandong University
2013-02 – 2014-12 · Purpura, Idiopathic Thrombocytopenic Purpura
What this study did
NCT02249767 · Spear Pharmaceuticals
2013-11 – 2014-06 · Acne
What this study did
NCT00003564 · M.D. Anderson Cancer Center
— · Brain and Central Nervous System Tumors
What this study did
NCT01243450 · Spear Pharmaceuticals
2009-10 – 2010-10 · Acne
What this study did
NCT00838812 · Igefarma Laboratorios S.A.
2009-03 – 2010-04 · Acne Vulgaris
What this study did
NCT01135069 · Spear Pharmaceuticals
2009-10 – 2010-04 · Acne
What this study did
NCT00647556 · Galderma R&D
2008-04 – 2010-01 · Photoaging
What this study did
NCT00004188 · Children's Oncology Group
2001-02 – 2007-10 · Neuroblastoma
What this study did
NCT00007631 · US Department of Veterans Affairs
1998-03 – 2006-07 · Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms
What this study did
NCT00599937 · Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
1993-01 – 1998-12 · Leukemia, Promyelocytic, Acute
What this study did
Phase 2/3 (5)
Acute Myeloid Leukemia
NCT05175508 · The First Affiliated Hospital of Soochow University
2021-05-01 – 2023-05-01 · AML, MDS, Old Age; Debility, Hematologic Cancer
What this study did
Other / comorbidity
NCT07626398 · Beijing Anzhen Hospital
2026-06-01 – 2029-06-01 · Hemophagocytic Lymphohistiocytosis (HLH)
What this study did
NCT07278908 · Institute of Hematology & Blood Diseases Hospital, China
2025-12 – 2028-12 · ITP - Immune Thrombocytopenia
What this study did
NCT00717652 · Azidus Brasil
2008-07 – 2008-07 · Melasma
What this study did
Phase 2 (74)
Acute Myeloid Leukemia
NCT01409161 · M.D. Anderson Cancer Center
2011-10-05 – 2027-12-18 · Acute Promyelocytic Leukemia With PML-RARA
What this study did
NCT04793919 · Associazione Italiana Ematologia Oncologia Pediatrica
2019-10-09 – 2027-10-10 · Acute Promyelocytic Leukemia
What this study did
NCT03624270 · The University of Hong Kong
2018-08-15 – 2023-12-31 · Acute Promyelocytic Leukemia
What this study did
NCT01404949 · Memorial Sloan Kettering Cancer Center
2011-07 – 2021-02-01 · Acute Promyelocytic Leukemia
What this study did
NCT01064570 · Gruppo Italiano Malattie EMatologiche dell'Adulto
started 2000-05 · Acute Promyelocytic Leukemia
What this study did
NCT02942758 · University Hospital Regensburg
2017-04-10 – 2020-03-25 · Acute Myeloid Leukemia
What this study did
NCT00551460 · SWOG Cancer Research Network
2007-11-15 – 2018-02-05 · Leukemia
What this study did
NCT00867672 · University Hospital Freiburg
2011-08 – 2016-02 · Acute Myeloid Leukemia
What this study did
NCT00413166 · M.D. Anderson Cancer Center
2006-12 – 2016-02 · Acute Promyelocytic Leukemia
What this study did
NCT00276601 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2004-10 – 2013-06 · Leukemia
What this study did
NCT00528450 · Memorial Sloan Kettering Cancer Center
2007-09 – 2011-01 · Leukemia
What this study did
NCT00339196 · Assistance Publique - Hôpitaux de Paris
2006-07 – 2008-07 · Acute Myelogenous Leukaemia (AML), Myelodysplastic Syndrome (MDS)
What this study did
NCT00326170 · M.D. Anderson Cancer Center
2005-07 – 2007-12 · Myelodysplastic Syndrome, Acute Myelogenous Leukemia
What this study did
NCT00016159 · Memorial Sloan Kettering Cancer Center
2000-11 – 2007-03 · Leukemia
What this study did
NCT00136461 · Dana-Farber Cancer Institute
1997-05 – 2000-08 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
Other / comorbidity
NCT06703047 · Fudan University
2024-11-20 – 2030-10-24 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06358677 · University of Utah
2025-02-19 – 2029-07 · Metastatic Solid Tumor, Locally Advanced Solid Tumor
What this study did
NCT04241276 · Queen Mary University of London
2020-04-30 – 2029-02-28 · Pancreatic Cancer
What this study did
NCT07355855 · Fudan University
2026-01 – 2029-01 · Rhabdomyosarcoma
What this study did
NCT05999812 · University of Texas Southwestern Medical Center
2023-12-19 – 2028-10-01 · Colorectal Cancer
What this study did
NCT05345002 · Stephen Bagley, MD, MSCE
2022-11-16 – 2028-06-01 · Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
What this study did
NCT07586826 · Peking University People's Hospital
2025-12-22 – 2027-12-31 · Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT07586813 · Peking University People's Hospital
2025-12-22 – 2027-12-31 · Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer, Colorectal Cancer
What this study did
NCT06528769 · Gabriel Tinoco
2025-09-10 – 2027-12-31 · Leiomyosarcoma, Sarcoma
What this study did
NCT06646666 · Ruijin Hospital
2024-12-01 – 2027-12-01 · B-cell Non Hodgkin Lymphoma
What this study did
NCT06731140 · Fudan University
2025-02-12 – 2027-10 · HER2 Negative Breast Cancer
What this study did
NCT04385277 · Children's Oncology Group
2020-12-31 – 2027-09-30 · Ganglioneuroblastoma, Nodular, Neuroblastoma
What this study did
NCT07079696 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-09-01 – 2027-01 · Dup15q Syndrome, Autism Spectrum Disorder, Therapy, All-trans Retinoic Acid
What this study did
NCT06728631 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2020-06-30 – 2026-12-31 · Oral Cavity Cancer, Premalignant Lesion
What this study did
NCT03786783 · National Cancer Institute (NCI)
2019-03-04 – 2026-03-31 · Ganglioneuroblastoma, High Risk Neuroblastoma
What this study did
NCT06158412 · The First Affiliated Hospital of Xiamen University
2023-11-22 – 2025-12-31 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT01857934 · St. Jude Children's Research Hospital
2013-07-05 – 2025-12-31 · Neuroblastoma
What this study did
NCT06484920 · Rita Assi
2024-11-18 – 2025-06-03 · Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, B-cell Lymphoma
What this study did
NCT04113863 · Mario Negri Institute for Pharmacological Research
2019-06-18 – 2025-01-30 · Breast Neoplasm Female
What this study did
NCT04700176 · Hackensack Meridian Health
2022-05-02 – 2023-11-15 · Multiple Myeloma
What this study did
NCT06013540 · Jinnah Postgraduate Medical Centre
2022-08-01 – 2023-08-30 · Melasma
What this study did
NCT04433169 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2020-06-03 – 2023-06 · Adenoid Cystic Carcinoma of the Head and Neck
What this study did
NCT02403778 · University of Colorado, Denver
2015-12-17 – 2023-01-18 · Melanoma
What this study did
NCT03572387 · Icahn School of Medicine at Mount Sinai
2018-08-20 – 2022-07-08 · Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
What this study did
NCT04618328 · Peking University People's Hospital
2020-11 – 2021-10 · Immune Thrombocytopenia
What this study did
NCT03304288 · Peking University People's Hospital
2017-10-11 – 2021-02-28 · Immune Thrombocytopenia
What this study did
NCT03359174 · Yale University
2018-05-29 – 2021-01-01 · Cholangitis, Sclerosing
What this study did
NCT04568096 · Kafrelsheikh University
2020-11 – 2020-12 · the Lung Complication of COVID-19
What this study did
NCT04217148 · Peking University People's Hospital
2020-01-01 – 2020-06-30 · Immune Thrombocytopenia
What this study did
NCT03999684 · Dana-Farber Cancer Institute
2019-08-05 – 2020-04-15 · Adenoid Cystic Carcinoma
What this study did
NCT00617409 · H. Lee Moffitt Cancer Center and Research Institute
2007-10-02 – 2019-01-31 · Small Cell Lung Cancer
What this study did
Phase 1/2 (26)
Acute Myeloid Leukemia
NCT07926607 · Second Affiliated Hospital of Nanchang University
2026-11-01 – 2029-12-31 · Acute Myeloblastic Leukemia
What this study did
NCT03031249 · Institute of Hematology & Blood Diseases Hospital, China
2017-02-08 – 2027-10-15 · AML
What this study did
NCT02717884 · Michael Luebbert
2015-05 – 2021-12 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT02842827 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
2016-10-06 – 2018-10-30 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT02261779 · Martin-Luther-Universität Halle-Wittenberg
2014-09 – 2017-09 · AML
What this study did
NCT00995332 · University of Bergen
2009-09 – 2013-06 · Acute Myelogenous Leukemia
What this study did
NCT00175812 · University of Bergen
2004-11 – 2009-11 · Acute Myelogenous Leukemia
What this study did
Other / comorbidity
NCT07848568 · Children's Oncology Group
2026-12-11 – 2037-06-30 · Childhood Posterior Fossa Ependymoma
What this study did
NCT06536413 · The Methodist Hospital Research Institute
2024-07-29 – 2030-07 · Multiple Myeloma
What this study did
NCT06439888 · Gustave Roussy, Cancer Campus, Grand Paris
2024-07-11 – 2027-01 · Oligometastatic Disease, Solid Tumor, Adult
What this study did
NCT06020833 · Peking Union Medical College Hospital
2023-08 – 2026-12 · Myelodysplastic Syndromes
What this study did
NCT05497310 · Hospital Universitario Dr. Jose E. Gonzalez
2022-07-01 – 2025-07-31 · Promyelocytic Leukemia
What this study did
NCT04730895 · Kafrelsheikh University
2021-07 – 2023-12 · Covid19 Vaccine
What this study did
NCT00382200 · Memorial Sloan Kettering Cancer Center
2006-07 – 2023-01-05 · Myelodysplastic Syndromes
What this study did
NCT03200847 · University of Colorado, Denver
2017-10-31 – 2022-10-19 · Stage IV Melanoma, Stage III Melanoma, Advanced Melanoma
What this study did
NCT02751255 · Amsterdam UMC, location VUmc
2016-07-06 – 2022-10-18 · Multiple Myeloma
What this study did
NCT02712905 · Incyte Corporation
2016-05-05 – 2022-04-14 · Solid Tumors and Hematologic Malignancy
What this study did
NCT01701479 · St. Anna Kinderkrebsforschung
2012-01 – 2020-12 · Neuroblastoma
What this study did
NCT00555399 · M.D. Anderson Cancer Center
2007-11-28 – 2020-01-24 · Glioblastoma Multiforme, Anaplastic Glioma
What this study did
NCT03259516 · St. Petersburg State Pavlov Medical University
2017-05-25 – 2018-12-25 · Myelodysplastic Syndromes
What this study did
NCT01592045 · United Therapeutics
2012-08 – 2014-06 · Neuroblastoma
What this study did
NCT00919555 · Phoenix Neurological Associates, LTD
2008-06 – 2012-03 · Amyotrophic Lateral Sclerosis
What this study did
NCT00006220 · Washington University School of Medicine
1999-06 – 2002-02 · Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
What this study did
Phase 1 (29)
Acute Myeloid Leukemia
NCT04282668 · Taiho Oncology, Inc.
2020-03-15 – 2024-02-12 · Acute Myeloid Leukemia
What this study did
NCT05297123 · First Affiliated Hospital Xi'an Jiaotong University
2019-02-03 – 2023-12-31 · Acute Myeloid Leukemia
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01020539 · Columbia University
2002-09-11 – 2020-12 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
What this study did
NCT02273102 · University of Miami
2015-03-02 – 2020-07-01 · Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Leukemia
What this study did
NCT02177812 · GlaxoSmithKline
2014-08-27 – 2017-12-08 · Leukaemia, Myelocytic, Acute
What this study did
NCT00892190 · University of Pittsburgh
2011-04 – 2016-02 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT01820624 · Paolo Caimi, MD
2013-04-30 – 2015-11-13 · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
What this study did
NCT01161550 · Washington University School of Medicine
2010-11 – 2012-08 · Leukemia, Myeloid, Acute
What this study did
Other / comorbidity
NCT07842887 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-10-01 – 2028-10-10 · EGFR-TKI-resistant Non-Small Cell Lung Cancer
What this study did
NCT01711554 · National Cancer Institute (NCI)
2013-02-04 – 2027-03-03 · Recurrent Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT07348107 · Daniel Breadner
2026-02-15 – 2027-03 · Advanced Pancreatic Ductal Adenocarcinoma
What this study did
NCT04919369 · Dwight Owen
2021-10-18 – 2026-07-03 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT01175356 · Children's Oncology Group
2011-12-21 – 2025-12-31 · Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
What this study did
NCT05482451 · China Medical University Hospital
2021-03-01 – 2025-02-28 · Effect of Drug
What this study did
NCT03491267 · Johns Hopkins University
2018-01-01 – 2024-11-01 · Central Centrifugal Cicatricial Alopecia (CCCA)
What this study did
NCT05281965 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-04-01 – 2024-06-01 · Autism, Treatment Adherence, Retinoic Acid, Dup15Q Syndrome
What this study did
NCT00867178 · National Cancer Institute (NCI)
2009-02-25 – 2021-12-22 · Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
What this study did
NCT03307148 · Barts & The London NHS Trust
2016-01-15 – 2019-03-19 · Pancreatic Adenocarcinoma
What this study did
NCT00334789 · National Cancer Institute (NCI)
2006-06-12 – 2018-03-29 · Adult Solid Neoplasm
What this study did
NCT03392623 · Universidad Autonoma de San Luis Potosí
2015-01-01 – 2016-12-01 · Melasma
What this study did
NCT02401295 · University of Iowa
2015-05 – 2016-11 · Relapsed Multiple Myeloma
What this study did
NCT01456468 · Yale University
2011-10 – 2015-12 · Cholangitis, Sclerosing
What this study did
NCT01985477 · M.D. Anderson Cancer Center
2013-12 – 2015-09 · Myeloma
What this study did
NCT02497833 · Sun Yat-sen University
2014-11 – 2015-05 · Hypercholesterolemia
What this study did
NCT01208454 · National Cancer Institute (NCI)
2010-12 – 2014-09 · Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
What this study did
NCT00533169 · M.D. Anderson Cancer Center
2007-09 – 2011-02 · Neuroblastoma
What this study did
NCT00400556 · Peter MacCallum Cancer Centre, Australia
2005-03 – 2005-05 · Multiple Myeloma, Cutaneous Lymphoma
What this study did
NCT00006239 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2000-12 – 2005-03 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
What this study did
Phase 4 (21)
Acute Myeloid Leukemia
NCT02200978 · South China Children's Leukemia Group
2011-09 – 2021-10 · Childhood Acute Promyelocytic Leukemia
What this study did
NCT01987297 · Shanghai Jiao Tong University School of Medicine
2012-06 – 2020-12-31 · Acute Promyelocytic Leukemia
What this study did
NCT00504764 · PETHEMA Foundation
2007-07 – 2014-10 · Acute Promyelocytic Leukemia
What this study did
NCT00408278 · PETHEMA Foundation
2005-07 – 2013-12 · Acute Promyelocytic Leukemia
What this study did
NCT00465933 · PETHEMA Foundation
1999-03 – 2007-11 · Acute Promyelocytic Leukemia
What this study did
Other / comorbidity
NCT07932288 · Colgate Palmolive
2026-10-28 – 2027-06 · Acne
What this study did
NCT07012811 · Latakia University
2024-02-12 – 2025-03-30 · Plane Warts
What this study did
NCT04324411 · Peking Union Medical College Hospital
2020-04-20 – 2023-09-01 · Autoimmune Anemia
What this study did
NCT04096742 · Goldman, Butterwick, Fitzpatrick and Groff
2019-08-06 – 2021-12-31 · Photodamaged Skin, Photoaging
What this study did
NCT02020161 · PETHEMA Foundation
2012-06 – 2021-12 · APL
What this study did
NCT01522456 · Galderma R&D
2012-04 – 2012-05 · Acne Vulgaris
What this study did
NCT01206348 · Medicis Global Service Corporation
2010-09 – 2011-07 · Acne
What this study did
NCT01313728 · Bausch Health Americas, Inc.
2010-12 – 2011-01 · Acne Vulgaris
What this study did
NCT01404130 · University of Aberdeen
2008-09 – 2010-11 · Acne Vulgaris
What this study did
NCT01047189 · Wake Forest University
2009-03 – 2009-10 · Acne Vulgaris
What this study did
NCT00835198 · Allergan
2008-12 – 2009-08 · Acne Vulgaris
What this study did
NCT00472966 · Galderma R&D
2006-11 – 2007-04 · Melasma
What this study did
NCT00469183 · Galderma R&D
2006-05 – 2007-04 · Melasma
What this study did
NCT00240513 · Derm Research @ 888 Inc.
2004-08 – 2006-12 · Acne Vulgaris
What this study did
Early phase / not applicable (13)
Acute Myeloid Leukemia
NCT06841952 · The First Affiliated Hospital of Soochow University
2025-02-15 – 2030-12-15 · AML, Adult
What this study did
NCT07187505 · Anhui Medical University
2025-07-01 – 2027-07-01 · Acute Promyelocytic Leukemia (APL)
What this study did
Other / comorbidity
NCT06371274 · First Affiliated Hospital of Zhejiang University
2024-10-10 – 2026-04-30 · Triple-negative Breast Cancer
What this study did
NCT07142070 · Medipol University
2025-09-01 – 2026-02-01 · Periodontal Diseases, Inflammation
What this study did
NCT06571721 · Integrative Skin Science and Research
2024-07-22 – 2025-07-22 · Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin, Sebum Deficiency
What this study did
NCT06181838 · Universitas Indonesia
2023-08-28 – 2024-01-03 · Acne Vulgaris, Quality of Life
What this study did
NCT03574701 · St. Paul's Hospital, Canada
2016-05-25 – 2022-12-25 · Olfactory Disorder
What this study did
NCT01064557 · Gruppo Italiano Malattie EMatologiche dell'Adulto
1993-10 – 2020-12 · Leukemia
What this study did
NCT04417348 · Universidad Autonoma de San Luis Potosí
2019-01-31 – 2019-12-15 · Melasma
What this study did
NCT01349556 · Johns Hopkins University
2011-05 – 2014-03 · Medication Reaction
What this study did
NCT01257906 · Actavis Mid-Atlantic LLC
2010-05 – 2010-10 · MILD TO SEVERE ACNE VULGARIS
What this study did
NCT00003598 · University of Michigan Rogel Cancer Center
1999-01 – 2009-11 · Cervical Cancer, Precancerous/Nonmalignant Condition
What this study did
NCT00440024 · University of Michigan
2007-02 – 2009-11 · Sun-Damaged Skin, Retinoid Intolerance
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Acute Myeloid Leukemia
NCT00962767 · Wyeth is now a wholly owned subsidiary of Pfizer
2002-05 – 2007-12 · Leukemia, Myelocytic, Acute
What this study did
Other / comorbidity
NCT00689117 · Stiefel, a GSK Company
2008-04 – 2009-05 · Acne Vulgaris, Acne
What this study did
Phase 2 (3)
Other / comorbidity
NCT07366229 · Shenzhen People's Hospital
2025-12-30 – 2026-06-30 · Acne
What this study did
NCT05461755 · Merete Haedersdal
2022-11-22 – 2023-07-05 · Striae Distensae
What this study did
NCT04080869 · Assiut University
2020-01-06 – 2020-11-30 · Facial Acne Vulgaris
What this study did
Phase 1 (1)
Other / comorbidity
NCT07154030 · Sohag University
2025-09-05 – 2026-09-05 · Striae
What this study did
Phase 4 (1)
Other / comorbidity
NCT01149876 · Massachusetts General Hospital
2010-06 – 2011-12 · Hyperpigmentation
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT00974480 · Cosmetique Active International
2009-09 – 2010-07 · Skin Aging
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Early phase / not applicable (1)
Appears in other studies (40)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (6)
Acute Myeloid Leukemia
NCT07504458 · Quetzal Therapeutics
2026-06-08 – 2030-12 · Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Acute Promyelocytic Leukemia
What this study did
NCT07296445 · SDK Therapeutics, Inc.
2026-01 – 2029-01 · Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, APL, Acute Promyelocytic Leukemia, Leukaemia, Leukemia Acute Promyelocytic Leukemia (APL), Leukemia, Acute
What this study did
NCT07503730 · First Affiliated Hospital Xi'an Jiaotong University
2025-06-01 – 2028-06 · APL
What this study did
NCT04175587 · Peking University People's Hospital
2019-12-01 – 2023-08-31 · Acute Promyelocytic Leukaemia
What this study did
Other / comorbidity
NCT00026312 · National Cancer Institute (NCI)
2001-10-26 – 2025-12-31 · Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
What this study did
NCT01406080 · Galderma Brasil Ltda.
2013-01 – 2015-11 · Photoaging, Photodamage
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT07084116 · James Thomas Pathoulas
2025-07-14 – 2026-05-24 · Skin Tear, Solar Purpura, Dermatoporosis
What this study did
NCT06787222 · Hasanuddin University
2024-11-03 – 2025-10-31 · Acne Vulgaris
What this study did
NCT00823901 · Massachusetts General Hospital
2009-02 – 2010-10 · Rosacea
What this study did
Phase 2 (3)
Other / comorbidity
NCT02278861 · Universidade Federal de Goias
2011-11 – 2014-05 · Actinic Keratosis
What this study did
NCT00842907 · Federal University of São Paulo
2009-05 – 2010-08 · Photodamage, Photoaging
What this study did
NCT00621218 · Coria Laboratories, Ltd.
2008-02 – 2008-12 · Rosacea
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07015931 · Universitas Indonesia
2024-11-30 – 2025-03-15 · Acne Vulgaris
What this study did
Phase 1 (11)
Other / comorbidity
NCT07469228 · Sun Pharmaceutical Industries, Inc.
2025-08-04 – 2025-12-15 · Acne Vulgaris
What this study did
NCT04883736 · Sun Pharmaceutical Industries, Inc.
2020-08-31 – 2021-04-16 · Acne Vulgaris
What this study did
NCT04724473 · Sun Pharmaceutical Industries, Inc.
2019-12-10 – 2020-11-21 · Acne Vulgaris
What this study did
NCT03433378 · Sun Pharmaceutical Industries, Inc.
2017-08-04 – 2018-01-26 · Acne Vulgaris
What this study did
NCT03427554 · Sun Pharmaceutical Industries, Inc.
2017-08-21 – 2018-01-26 · Acne Vulgaris
What this study did
NCT02620813 · University of California, Davis
2015-10 – 2017-10-12 · Acne Vulgaris
What this study did
NCT02410980 · University of California, Irvine
2015-08 – 2016-12 · Collagen Fibril Alteration
What this study did
NCT00603772 · Coria Laboratories, Ltd.
2008-01 – 2008-03 · Healthy
What this study did
NCT00604032 · Coria Laboratories, Ltd.
2008-01 – 2008-02 · Healthy
What this study did
Phase 4 (11)
Other / comorbidity
NCT07915648 · Nishtar Medical University
2026-09-17 – 2027-03-16 · Acne Vulgaris
What this study did
NCT07732192 · Combined Military Hospital Abbottabad
2026-07-15 – 2027-02-01 · Melasma, Melasma (Facial Melasma)
What this study did
NCT01422785 · Zeichner, Joshua, M.D.
2011-07 – 2011-12 · Acne Vulgaris
What this study did
NCT01448733 · Zeichner, Joshua, M.D.
2011-07 – 2011-10 · Acne Vulgaris
What this study did
NCT00939133 · Dermatrials Research
2009-07 – 2010-12 · Acne
What this study did
NCT01027793 · Hexsel Dermatology Clinic
2009-03 – 2010-08 · Stretch Marks, Striae, Treatment
What this study did
NCT01111994 · Callender Center for Clinical Research
2009-11 – 2010-04 · Acne
What this study did
NCT00952523 · Bausch Health Americas, Inc.
2009-07 – 2009-10 · Acne Vulgaris
What this study did
NCT00907257 · Bausch Health Americas, Inc.
2009-02 – 2009-09 · Acne Vulgaris
What this study did
NCT00919191 · Bausch Health Americas, Inc.
2009-04 – 2009-05 · Acne Vulgaris
What this study did
NCT00714714 · Bausch Health Americas, Inc.
2008-01 – 2008-02 · Acne Vulgaris
What this study did
Early phase / not applicable (5)
Other / comorbidity
NCT07927920 · Combined Military Hospital, Pakistan
2026-12 – 2027-07 · Plane Warts
What this study did
NCT06008327 · Jinnah Postgraduate Medical Centre
2022-08-01 – 2023-06-20 · Acanthosis Nigricans
What this study did
NCT05004909 · Dr.dr.Irma Bernadette, SpKK (K)
2021-09-01 – 2022-01-31 · Photoaging
What this study did
NCT03933774 · The Catholic University of Korea
2019-04-29 – 2019-11-29 · Vitiligo
What this study did
NCT02704507 · Carilion Clinic
2015-06 – 2016-06 · Acne
What this study did

Competitive landscape

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tretinoin (Vesanoid): this drugApprovedSmall moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race

Large race: only the 60 furthest-along competitors are listed; 70 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vesanoid (Tretinoin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (12)
January 2027 (1)
Phase 2Dup15q Syndrome, Autism Spectrum Disorder, Therapy, All-trans Retinoic AcidNot yet recruiting
Est. primary completion 2027-01 · NCT07079696 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Advanced Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-03 · NCT07348107 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4AcneEnrolling by invitation
Est. primary completion 2027-05 · NCT07932288 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2B-cell Non Hodgkin LymphomaNot yet recruiting
Est. primary completion 2027-06-01 · NCT06646666 · CT.gov ↗
What to watch
Phase 2Glioma, IDH Mutation, Astrocytoma, OligodendrogliomaRecruiting
Est. primary completion 2027-06-01 · NCT05345002 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Metastatic Solid Tumor, Locally Advanced Solid TumorRecruiting
Est. primary completion 2027-07 · NCT06358677 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-07-01 · NCT07187505 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer …Recruiting
Est. primary completion 2027-10-31 · NCT07586826 · CT.gov ↗
What to watch
Phase 2Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms …Recruiting
Est. primary completion 2027-10-31 · NCT07586813 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-18 · NCT01409161 · CT.gov ↗
What to watch
Phase 3Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07597395 · CT.gov ↗
What to watch
Phase 2Leiomyosarcoma, SarcomaRecruiting
Est. primary completion 2027-12-31 · NCT06528769 · CT.gov ↗
What to watch
2028 (5)
June 2028 (2)
Phase 2/3Hemophagocytic Lymphohistiocytosis (HLH)Not yet recruiting
Est. primary completion 2028-06-01 · NCT07626398 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2028-06-29 · NCT04241276 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1EGFR-TKI-resistant Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07842887 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2/3ITP - Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2028-12 · NCT07278908 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-12-15 · NCT06841952 · CT.gov ↗
What to watch
2029 (6)
January 2029 (2)
Phase 2RhabdomyosarcomaNot yet recruiting
Est. primary completion 2029-01 · NCT07355855 · CT.gov ↗
What to watch
Phase 3Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck TumorRecruiting
Est. primary completion 2029-01 · NCT06706401 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-07 · NCT06536413 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Triple Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2029-09 · NCT06636981 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-11-20 · NCT06703047 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07926607 · CT.gov ↗
What to watch
2037 (1)
June 2037 (1)
Phase 1/2Childhood Posterior Fossa EpendymomaNot yet recruiting
Est. primary completion 2037-06-30 · NCT07848568 · CT.gov ↗
What to watch

See the full readout calendar ↗